Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $231,876.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the sale, the chief financial officer directly owned 174,693 shares of the company’s stock, valued at $14,213,022.48. The trade was a 1.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Down 1.5%

Shares of NASDAQ:ANIP opened at $79.24 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $62.60 and a 1 year high of $99.50. The company has a market capitalization of $1.80 billion, a PE ratio of 20.06 and a beta of 0.43. The business has a fifty day moving average price of $81.13 and a two-hundred day moving average price of $79.52. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the period. State Street Corp boosted its holdings in ANI Pharmaceuticals by 2.2% in the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after buying an additional 15,496 shares during the period. UBS Group AG boosted its holdings in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after buying an additional 91,153 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in ANI Pharmaceuticals by 8.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after buying an additional 43,523 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

ANIP has been the subject of a number of research reports. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Guggenheim reissued a “buy” rating and set a $124.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Finally, Canaccord Genuity Group initiated coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They issued a “hold” rating and a $91.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $105.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.